生物活性天然产品的纳米输送:针对动脉样硬化治疗的有针对性的治疗突破
Chen Liu1, Peichen Wang1, Renjun Gu2
1School of Acupuncture-Moxibustion and Tuina, School of Health Preservation and Rehabilitation, Nanjing University of Chinese Medicine, Nanjing 210023, China.
Pharmaceutics
|September 27, 2025
概括
生物活性天然产品 (BNPs) 对动脉样硬化症 (AS) 治疗有前途,但遭受不良交付. 纳米粒子药物递送系统 (NDDS) 增强了BNPs.
科学领域:
- 药理学和治疗学 药理学和治疗学
- 心血管医学 心血管医学
- 自然产品化学 自然产品化学
背景情况:
- 动脉样硬化 (AS) 是一种复杂的心血管疾病,治疗选择有限.
- 生物活性天然产品 (BNPs) 具有有利于AS的多目标能力.
- 传统的BNPs面临着生物可用性差,AS治疗向性不足的挑战.
研究的目的:
- 审查生物活性天然产品 (BNPs) 与用于动脉样硬化 (AS) 治疗的纳米颗粒药物递送系统 (NDDS) 的整合.
- 分析NDDS如何克服AS治疗中BNPs的局限性.
- 探索使用增强的BNPs治疗AS的新型治疗策略.
主要方法:
- 对AS的BNPs (,烯,) 与NDDS结合的研究进行系统审查.
- 分析NDDS设计策略及其对药物动力学特性及其向效率的影响.
- 评估NDDS-BNPs调节AS病理过程的机制.
主要成果:
- 在AS模型中,NDDS显著提高了BNPs的生物可用性,溶解性和向性.
- NDDS策略增强药物稳定性,并使BNPs的控制释放成为可能.
- 组合疗法通过抗氧化,抗炎和脂质调节效应有效地干预AS的病变发生.
结论:
- 将BNPs与NDDS结合起来是一个有希望的策略,可以克服AS治疗的临床限制.
- NDDS优化了用于治疗动脉样硬化的天然化合物的输送和有效性.
- 这种方法为开发心血管疾病有效疗法提供了创新的途径.
更多相关视频
09:06Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice
Published on: February 20, 2019
8.8K
10:50Osmotic Drug Delivery to Ischemic Hindlimbs and Perfusion of Vasculature with Microfil for Micro-Computed Tomography Imaging
Published on: June 29, 2013
12.7K
相关概念视频
01:27Bioavailability Enhancement: Drug Permeability Enhancement
186
Body:After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt...
186
01:26Atherosclerosis III: Management
321
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
321
01:16Drug Delivery: Overview
724
The selection of a drug's delivery route depends upon its physicochemical properties, including lipid or water solubility and ionization, as well as the therapeutic requirement, such as immediate or sustained effect. These routes can be divided into three primary categories: enteral, parenteral, and topical.
Enteral delivery involves administering drugs directly through swallowing, sublingual placement, or buccal application. Orally administered drugs predominantly navigate the...
Enteral delivery involves administering drugs directly through swallowing, sublingual placement, or buccal application. Orally administered drugs predominantly navigate the...
724
01:16Antianginal Drugs: Nitrates and β-Blockers
1.4K
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
1.4K
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.1K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.1K
01:26Targets for Drug Action: Overview
10.0K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
10.0K